INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
08/13/2026
Back to search
Official data from USPTO
CRESCENDO BIOLOGICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
08/13/2026
Classification
Registered
Trademark type
Combined
Nice classes
1, 5, 40
Filing date
10/21/2016
Registration date
06/12/2018
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/24/2025
Last transaction
08/13/2026
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
Cambridge, GB
Examiner
LEE, JEANIE H
Current location
Historical data usage
Mark description
The mark consists of a design of three circles each having U-shaped cut-outs. The three circles are centered above the stylized wording "Crescendo" directly above the stylised wording "biologics".
Holders and representatives
Holders
Crescendo Biologics Limited
Crescendo Biologics Limited
Representatives
Christopher J. Schulte Merchant & Gould P.C.
Technical classification
Nice Classes
Class 1Class 5Class 40
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industry and science; chemicals for laboratory research purposeschemical tests kits for in vitro testing; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicalmonoclonal antibodies for in vitro scientific or research use; biochemicalmonoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discoverypreclinical and clinical development of therapeutic products
Class 5
Pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; veterinary preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposestherapeutic pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; antibodiesbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; antibody fragmentsbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; monoclonal antibody therapies for therapeutic purposesbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; antibodies and antibody fragmentsbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseasesfor medical and veterinary diagnostics; antibodies and antibody fragmentsbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseasesfor use in the discoverypreclinical and clinical development of therapeutic products; antibodies and antibody fragmentsbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseasesfor use in the manufacture of therapeutic products
Class 40
Treatment and transformation of materials for othersnamely the custom manufacture of chemicalsbiologicalsantibodies and antibody fragments; contract manufacturing services in the field of chemicalsbiologicalsantibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragments
Publications
History of USPTO decisions and trademark events.
45 publications found
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
07/19/2026
INPC
INVALIDATION PROCESSED
07/19/2026
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
12/24/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
06/03/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
04/24/2025
71AG
REGISTERED-SEC.71 ACCEPTED
04/24/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/21/2025
ES71
TEAS SECTION 71 RECEIVED
12/04/2024
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
11/08/2024
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
10/27/2023
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
08/19/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/12/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/06/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/18/2018
FIMP
FINAL DISPOSITION PROCESSED
09/18/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/12/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
06/12/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/27/2018
PUBO
PUBLISHED FOR OPPOSITION
03/27/2018
GPNX
NOTIFICATION PROCESSED BY IB
03/24/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/07/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/07/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/07/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/16/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/14/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/14/2018
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/14/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/01/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/01/2018
CNFR
FINAL REFUSAL MAILED
01/12/2018
CNFR
FINAL REFUSAL WRITTEN
01/11/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/20/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/19/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/19/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/07/2017
RFNT
REFUSAL PROCESSED BY IB
07/14/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/23/2017
RFRR
REFUSAL PROCESSED BY MPU
06/23/2017
MAFR
APPLICATION FILING RECEIPT MAILED
06/16/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/15/2017
CNRT
NON-FINAL ACTION WRITTEN
06/14/2017
DOCK
ASSIGNED TO EXAMINER
06/12/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/12/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/08/2017
Continuous trademark protection
Get notified about every new filing that threatens CRESCENDO BIOLOGICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.